Please login to the form below
tafamidis
This page shows the latest tafamidis news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca and Ionis sign $3.6bn deal for eplontersen
However, if approved, eplontersen will not have the ATTR market to itself and must compete with Pfizer’s Vyndaqel/Vyndamax (tafamidis) and Alnylam’s RNAi therapy Onpattro (patisiran).
Latest news
-
Pfizer's 2021 revenue predictions soar to $82bn
In addition to $13bn in sales from Comirnaty, anticoagulant Eliquis (apixaban) grew by 19% to $1.3bn, amyloidosis therapy Vyndaqel/Vyndamax (tafamidis) was up by 42% to $502m and Inlyta increased
-
Pfizer CEO says COVID-19 vaccine efficacy data could come ‘soon’
This increase was helped by a 125% increase in global revenues for its rare disease med Vyndaqel (tafamidis), totalling $351m.
-
Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy
Vyndaqel (tafamidis meglumine) has been approved since 2011 for stage 1 polyneuropathy associated with ATTR, but the cardiomyopathy approval significantly extends the eligible patient population for the drug, already growing quickly
-
Vyndaqel a bright spot as Pfizer comes under pressure
The big boost for Pfizer came from Vyndaqel/Vyndamax (tafamidis) for rare disease transthyretin-mediated amyloidosis (ATTR), which swelled to $213m in the fourth quarter from just $39m a year earlier
-
Pfizer buys dwarfism drug company Therachon for $810m
The deal adds to Pfizer’s rare disease portfolio, which just chalked up a major success with the approval of tafamidis products Vyndaqel and Vyndamax for transthyretin amyloid cardiomyopathy (ATTR-CM)
More from news
Approximately 1 fully matching, plus 16 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance (palbociclib) and arthritis drug Xeljanz (tofacitinib), among others. ... Standing in its way is a similarly priced antisense rival from
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
produced impressive data for its Vyndaqel (tafamidis). ... Onpattro looked to have the edge in terms of clinical data, but Pfizer has new data showing tafamidis is effective in treating patients with cardiomyopathy – the heart damage caused by the
-
Tough times for pharma in Portugal
spondylitis. For instance, the Portuguese Association of Amyloidosis (APP) is petitioning parliament for access to Pfyzer's Vyndaqel (tafamidis).
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Consultant Dermatologist (Freelance)
-
£110-180ph
-
Head of Health Psychology, London
-
Highly competitive salary
-
Senior Health Psychologist, London
-
Highly competitive salary
- Senior Account Executive, Medical/ Brand Communications, London
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Recognising HIV Vaccine Awareness Day
- Scientists discover new approach to treat brain tumours
- Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data
- NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer
- Phase 3 trial of AstraZeneca and Avillion’s PT027 shows promise for asthma patients
- J&J appoints Thibaut Mongon as CEO designate of New Consumer Health Company
- Live Webinar: The Future of MedTech: Streamlined Clinical Data Collection & Management
- Medscape: Connect to the conversation
- A Medscape 4-part video interview series
- Why big pharma needs to be braver
- MadMicrobe Studios Inc Announces New European Venture
- EMA accepts Valneva’s marketing authorisation application for COVID-19 vaccine
PMHub
Mind+Matter
We are Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for our...
Latest intelligence
- Why big pharma needs to be braver
- The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
- Leveraging Real-World Evidence for Cell and Gene Therapies
- Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
- Food Allergy – Is avoidance the only option?
- Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
